Paolo Ghia Selected Research

Chlorambucil (Leukeran)

1/2022	Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
1/2022	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
1/2020	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
1/2020	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.
1/2020	Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.
11/2018	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
1/2018	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
12/2015	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paolo Ghia Research Topics

Disease

114	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/2022 - 03/2003
29	Neoplasms (Cancer) 01/2022 - 03/2003
15	Disease Progression 01/2022 - 07/2006
11	Leukemia 02/2022 - 08/2004
7	Lymphoma (Lymphomas) 01/2022 - 09/2002
7	Infections 11/2021 - 01/2017
7	Neutropenia 01/2020 - 12/2015
6	Lymphocytosis 01/2021 - 07/2009
6	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021 - 05/2013
5	COVID-19 11/2022 - 01/2020
5	Hemorrhage 01/2021 - 12/2015
5	Diarrhea 01/2021 - 12/2015
4	Residual Neoplasm 12/2021 - 01/2012
4	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2021 - 09/2011
3	Tumor Lysis Syndrome 01/2022 - 01/2019
3	Atrial Fibrillation 11/2021 - 10/2017
3	Fatigue 01/2019 - 12/2015
3	Hematologic Neoplasms (Hematological Malignancy) 12/2018 - 09/2013
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021 - 01/2019
2	Multiple Myeloma 04/2020 - 05/2003
2	Chromosome Aberrations (Chromosome Abnormalities) 01/2020 - 01/2019
2	Pneumonia (Pneumonitis) 01/2019 - 01/2017
2	Fever (Fevers) 12/2018 - 01/2017
2	Cough 12/2018 - 12/2015
2	Anemia 12/2018 - 12/2015
2	Nausea 12/2018 - 12/2015
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/2004 - 06/2003
1	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 01/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2021
1	Atrial Flutter (Flutter, Atrial) 11/2021
1	Agammaglobulinemia (Hypogammaglobulinemia) 07/2021
1	Arthralgia (Joint Pain) 01/2021
1	Headache (Headaches) 01/2021
1	Exanthema (Rash) 01/2021
1	Prostatic Neoplasms (Prostate Cancer) 12/2020
1	Starvation 12/2020

Drug/Important Bio-Agent (IBA)

27	ibrutinibIBA 05/2022 - 12/2015
24	Immunoglobulins (Immunoglobulin)IBA 01/2022 - 03/2004
18	AntigensIBA 01/2022 - 08/2004
15	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 01/2016
13	Rituximab (Mabthera)FDA Link 01/2022 - 09/2012
12	acalabrutinibIBA 01/2022 - 01/2016
9	Biological ProductsIBA 01/2022 - 09/2008
9	idelalisibIBA 01/2021 - 03/2014
8	Chlorambucil (Leukeran)FDA Link 01/2022 - 12/2015
7	Bendamustine Hydrochloride FDA Link 01/2022 - 09/2014
7	Proteins (Proteins, Gene)FDA Link 12/2020 - 06/2005
7	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2019 - 11/2011
6	ofatumumab FDA Link 01/2022 - 04/2015
5	Immunoglobulin M (IgM)IBA 01/2022 - 01/2014
5	fludarabineIBA 12/2019 - 05/2015
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2019 - 09/2012
4	Biomarkers (Surrogate Marker)IBA 04/2022 - 05/2015
3	Messenger RNA (mRNA)IBA 11/2022 - 06/2015
3	obinutuzumabIBA 01/2022 - 01/2020
3	EpitopesIBA 01/2021 - 11/2005
3	Pharmaceutical PreparationsIBA 01/2021 - 01/2013
3	Complementarity Determining Regions (Complementarity Determining Region)IBA 01/2021 - 01/2007
3	CytokinesIBA 01/2020 - 10/2003
3	ChemokinesIBA 10/2019 - 06/2003
3	Immunoglobulin D (IgD)IBA 01/2019 - 01/2014
3	Ribonucleases (Ribonuclease)IBA 04/2015 - 01/2011
2	BNT162 VaccineIBA 11/2022 - 10/2021
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022 - 01/2016
2	zanubrutinibIBA 01/2022 - 10/2020
2	Chimeric Antigen ReceptorsIBA 01/2022 - 05/2011
2	Lenalidomide (CC 5013)FDA Link 01/2022 - 10/2017
2	Oxygen (Dioxygen)IBA 12/2021 - 01/2020
2	venetoclaxIBA 12/2021 - 01/2021
2	Peptides (Polypeptides)IBA 01/2021 - 11/2005
2	IronIBA 12/2020 - 04/2020
2	duvelisibIBA 01/2020 - 12/2018
2	Transcription Factors (Transcription Factor)IBA 01/2019 - 04/2016
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2019 - 12/2018
2	serum P-component (CIt)IBA 11/2018 - 01/2018
2	AutoantigensIBA 11/2017 - 12/2007
2	Antigen Receptors (Antigen Receptor)IBA 10/2017 - 08/2014
2	MicroRNAs (MicroRNA)IBA 05/2013 - 05/2010
1	Potassium Channels (Potassium Channel)IBA 02/2022
1	Antiviral Agents (Antivirals)IBA 01/2022
1	Indicators and Reagents (Reagents)IBA 11/2021
1	COVID-19 VaccinesIBA 10/2021
1	VaccinesIBA 07/2021
1	Monoclonal AntibodiesIBA 01/2021
1	pirtobrutinibIBA 01/2021
1	A-factor (Streptomyces)IBA 01/2021
1	Cysteine (L-Cysteine)FDA Link 01/2021
1	bicalutamide (Casodex)FDA LinkGeneric 12/2020
1	Androgen Antagonists (Antiandrogens)IBA 12/2020
1	AndrogensIBA 12/2020
1	Bortezomib (Velcade)FDA Link 04/2020
1	Proteasome InhibitorsIBA 04/2020
1	LipidsIBA 04/2020
1	Proteasome Endopeptidase Complex (Proteasome)IBA 04/2020

Therapy/Procedure

34	Therapeutics 02/2022 - 09/2002
3	Immunotherapy 01/2021 - 11/2005
2	Salvage Therapy 01/2019 - 01/2018
2	Drug Therapy (Chemotherapy) 01/2018 - 03/2014
1	Palliative Care (Palliative Therapy) 11/2021
1	Critical Care (Surgical Intensive Care) 01/2020